Göttingen, Germany | July 31, 2025

Incucyte® CX3 System transforms continuous analysis of 3D cell models with confocal imaging and unmatched throughput

- New confocal fluorescence imaging minimizes photobleaching and phototoxicity effects, capturing clear images of live 3D culture
- Industry-leading throughput enables real-time analysis of up to six microplates in parallel, maximizing data generation
- Comprehensive, intuitive workflows with integrated data analysis empower every scientist to generate high-quality data from complex assays with greater speed and confidence

The life science group Sartorius launches the new Incucyte® CX3 Live-Cell Analysis System, delivering the most advanced capabilities for 3D cell culture applications. Expanding the Incucyte® instrument portfolio, the CX3 combines innovative confocal fluorescence imaging, flexible throughput, and powerful software to streamline workflows and accelerate decision-making across discovery and development.

“3D cell research is rapidly growing, yet scientists still lack the necessary tools or expertise to develop, validate, and perform 3D cell assays at scale,” explains Lindy O’Clair, Product Manager of Incucyte® Systems at Sartorius. “We developed the Incucyte® CX3 system and paired it with easy-to-use software to make studying 3D models more accessible than ever. Now, every scientist can gain a deeper understanding of cell health, growth, and morphology, while benefiting from throughput that is unmatched in the market.”

Equipped with new confocal imaging, the CX3 minimizes photobleaching and phototoxicity effects, producing clear images of complex, multi-cellular 3D models, while the cells remain in a controlled environment. Its optical module effortlessly switches between spinning disk confocal, wide-field fluorescence, HD phase, and brightfield without compromising cell integrity or function.

Flexible throughput is a key benefit unique to the Incucyte® platform, enabling real-time assays from flasks, dishes, and microplates—up to six 96-well plates simultaneously for maximum data generation. The new instrument further enhances research capabilities by facilitating seamless transition between 2D and 3D cell culture workflows. Supported by optimized reagents, assay kits, and intuitive software, it simplifies every step from setup to analysis, transforming complex kinetic data into actionable insights.

“Advanced cell models offer crucial insights into drug development, disease modeling, and personalized therapies,” adds O’Clair. “With this launch, we are empowering scientists to fully harness these exceptional research tools, speeding up the path to life-changing treatments for patients.”

More information about Incucyte® CX3:
https://www.sartorius.com/incucyte-cx3

A profile of Sartorius
Sartorius is a leading international partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. Based in Göttingen, Germany, the company has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. More than 13,500 employees work for customers around the globe.

Visit our Newsroom or follow us on LinkedIn.

Contact
Lisa Dabney
Head of Marketing Programs
Lab Products & Services Division
+1 734-474-7117
lisa.dabney@sartorius.com